Hutchison China Meditech Limited Block Listing Six Monthly Return (2876Y)

TIDMHCM

RNS Number : 2876Y

Hutchison China Meditech Limited

31 December 2019

Blocklisting Six Monthly Return

London: Tuesday, December 31, 2019: Hutchison China MediTech Limited ("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:

 
1.   Name of applicant:            Hutchison China MediTech Limited 
2.   Name of scheme:               (a)  Share Option Scheme conditionally adopted 
                                         by Hutchison China MediTech Limited 
                                         in 2005 ("2005 HCML Share Option Scheme") 
                                   (b)  Share Option Scheme conditionally adopted 
                                         by Hutchison China MediTech Limited 
                                         in 2015 ("2015 HCML Share Option Scheme") 
3.   Period of return:             From June 29, 2019 to December 28, 2019 
4.   Balance under scheme          (a)        2005 HCML Share Option Scheme: 2,067,910 
      from previous return:                    ordinary shares of US$0.1 each 
                                   (b)        2015 HCML Share Option Scheme: 23,130,970 
                                               ordinary shares of US$0.1 each 
5.   The amount by which           (a)  2005 HCML Share Option Scheme: Nil 
      the block scheme has 
      been increased, if 
      the scheme has been 
      increased since the 
      date of the last return: 
                                   (b)  2015 HCML Share Option Scheme: Nil 
6.   Number of securities          (a)  2005 HCML Share Option Scheme: 329,000 
      issued/allotted under 
      scheme during period: 
                                   (b)  2015 HCML Share Option Scheme: Nil 
7.   Balance under scheme          (a)  2005 HCML Share Option Scheme: 1,738,910 
      not yet issued/allotted            ordinary shares of US$0.1 each 
      at end of the period: 
                                   (b)  2015 HCML Share Option Scheme: 23,130,970 
                                         ordinary shares of US$0.1 each 
8.   Number and class of           25,198,880 ordinary shares of US$0.1 each 
      securities originally         admitted on June 17, 2019 (to replace the 
      listed and the date           Company's previous block admission schemes 
      of admission:                 following the Company's share subdivision 
                                    which took effect on May 30, 2019) 
 
 
 
 
9.   Total number of securities    666,906,450 ordinary shares of US$0.1 each 
      in issue at the end 
      of the period: 
Name of contact:                   Christian Hogg 
Address of contact:                Level 18, The Metropolis Tower, 10 Metropolis 
                                    Drive, Hung Hom, Kowloon, Hong Kong 
Telephone number of contact:       +852 2121 8200

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 490 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                             +852 2121 8200 
  Annie Cheng, Vice President                                 +1 (973) 567 3786 
  David Dible, Citigate Dewe Rogerson                         +44 7967 566 919 (Mobile) 
                                                              david.dible@citigatedewerogerson.com 
  Xuan Yang, Solebury Trout                                   +1 (415) 971 9412 (Mobile) 
                                                               xyang@troutgroup.com 
 
Media Enquiries 
  UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson      +44 7973 611 888 (Mobile) 
                                                               anthony.carlisle@cdrconsultancy.co.uk 
  Americas - Brad Miles, Solebury Trout                       +1 (917) 570 7340 (Mobile) 
                                                               bmiles@troutgroup.com 
  Hong Kong & Asia ex-China     - Joseph Chi Lo, Brunswick    +852 9850 5033 (Mobile) 
                                                               jlo@brunswickgroup.com 
                                - Zhou Yi, Brunswick          +852 9783 6894 (Mobile) 
                                                               yzhou@brunswickgroup.com 
  Mainland China - Sam Shen, Edelman                          +86 136 7179 1029 (Mobile) 
                                                               sam.shen@edelman.com 
 
Nominated Advisor 
  Atholl Tweedie, Panmure Gordon (UK) Limited                 +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BLRCKKDBBBDDCBN

(END) Dow Jones Newswires

December 31, 2019 02:00 ET (07:00 GMT)

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024